Lenalidomide
Brand name: Revlimid
Rank #7 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$2.15B
Total Cost
130,834
Total Claims
$2.15B
Total Cost
3,935
Prescribers
$16K
Cost per Claim
11,562
Beneficiaries
130,893
30-Day Fills
$548K
Avg Cost/Provider
33
Avg Claims/Provider
Share of Medicare Part D Spending
0.78%
of total Medicare Part D spending
$2.15B of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $2.15B total
🔎 Data Overview
Lenalidomide is the #7 most expensive drug in Medicare Part D, costing taxpayers $2.15B in 2023. The top 10 drugs alone account for roughly 20% of all Part D spending.
At $16,471 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $547,637 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $186,382 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Lenalidomide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Zachary Hruska | Nurse Practitioner | Charlottesville, VA | 479 | $9.0M |
| 2 | Catharine Skoog | Physician Assistant | Milwaukee, WI | 478 | $8.5M |
| 3 | Parameswaren Venugopal | Hematology-Oncology | Chicago, IL | 310 | $7.4M |
| 4 | Suzan Rosen | Nurse Practitioner | Miami, FL | 344 | $6.4M |
| 5 | Sarah Holstein | Hematology-Oncology | Omaha, NE | 354 | $5.8M |
| 6 | Shannon O'mahar | Hematology-Oncology | Madison, WI | 309 | $5.6M |
| 7 | Erin Pettijohn | Hematology-Oncology | Grand Rapids, MI | 323 | $5.2M |
| 8 | Keith Stockerl-Goldstein | Medical Oncology | Saint Louis, MO | 260 | $5.1M |
| 9 | Matthew Pianko | Hematology | Ann Arbor, MI | 265 | $5.0M |
| 10 | John Winters | Hematology-Oncology | Scarborough, ME | 259 | $4.8M |
| 11 | Tara Anderson | Physician Assistant | New Haven, CT | 273 | $4.8M |
| 12 | Michael Green | Hematology-Oncology | Baltimore, MD | 372 | $4.7M |
| 13 | Robert Byram | Nurse Practitioner | New Orleans, LA | 203 | $4.6M |
| 14 | Latha Sree Polavaram | Hematology-Oncology | Grand Rapids, MI | 256 | $4.4M |
| 15 | Larry Anderson | Hematopoietic Cell Transplantation and Cellular Therapy | Dallas, TX | 248 | $4.4M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 4 | Dulaglutide (Trulicity) | $2.99B | 2,175,100 |
| 5 | Rivaroxaban (Xarelto) | $2.45B | 2,628,123 |
| 6 | Adalimumab (Humira(Cf) Pen) | $2.17B | 240,925 |
| 7 | Lenalidomide (Revlimid) | $2.15B | 130,834 |
| 8 | Insulin Glargine,hum.Rec.Anlog (Lantus Solostar) | $1.94B | 3,118,259 |
| 9 | Fluticasone/Umeclidin/Vilanter (Trelegy Ellipta) | $1.81B | 2,046,216 |
| 10 | Dapagliflozin Propanediol (Farxiga) | $1.65B | 1,666,200 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology